Core Viewpoint - Beixin Life Technology Co., Ltd. successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking a significant milestone for the company and the medical device industry in 2024 [1][3]. Company Overview - Beixin Life is the first medical device company to successfully list under the fifth set of standards of the Sci-Tech Innovation Board and the first medical device company to list in 2024 [1]. - The company focuses on cardiovascular disease diagnosis and treatment, with core products including the IVUS system and FFR system, which are recognized for their innovation and clinical significance [3][5]. Product Highlights - The IVUS system is China's first domestically developed 60MHz high-definition and high-speed IVUS product, designed to guide percutaneous coronary intervention (PCI) strategies [3]. - The FFR system is considered the gold standard for PCI treatment guidance and has received high-level recommendations from various guidelines and expert consensus [3][5]. Research and Development - Beixin Life emphasizes independent research and technological innovation, establishing multiple core technology platforms to support product upgrades and expansions [4]. - The company has a dedicated R&D team of 109 members, with over 40% holding doctoral or master's degrees, highlighting its commitment to talent as a core competitive advantage [4]. Intellectual Property - Beixin Life has developed a comprehensive intellectual property system, holding 185 authorized patents, including 86 invention patents and 14 PCT international patent applications [5]. Market Position and Future Outlook - The company aims to leverage its listing to enhance innovation, global market expansion, and capital collaboration, positioning itself as a leader in intelligent and precise cardiovascular intervention [6]. - The cardiovascular disease intervention market is seen as a rapidly evolving sector with significant clinical demand, presenting a strategic opportunity for Beixin Life to achieve its vision of becoming a world-class medical technology enterprise [5].
北芯生命登陆科创板 加速领航心血管智能化精准介入诊疗